Efficacy of roxadustat for diabetic nephropathy anemia patients in different stages of CKD and its effect on factors associated with renal fibrosis

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100044616

Enrollment

Unknown

Registered

2021-03-24

Start date

2020-02-01

Completion date

Unknown

Last updated

2021-10-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

anemia patients in different stages of chronic kidney diseases

Interventions

anemia patients in different stages of chronic kidney diseases (CKD):roxadustat

Eligibility

Sex/Gender

All

Age

30 Years to 76 Years

Inclusion criteria

Inclusion criteria: 1. Patients had chronic kidney disease with renal anemia: adults living in sea-level areas, male hemoglobin (Hb) <130 g/L, nonpregnant women Hb <120 g/L, and pregnant women < 110 g/L; 2. Agree to be treated with roxadustat; 3. It is necessary to take medicine according to the doctor's orders.

Exclusion criteria

Exclusion criteria: 1. Combined chronic diseases of the heart, brain, or other parts of the body; malignant tumors; 2. Patients who had not received EPO treatment in the last 4 weeks.

Design outcomes

Primary

Measure	Time frame
hemoglobin;serum ferritin;transferrin;TGF-beta 1;ECM;	—

Secondary

Measure	Time frame
hepcidin;CTGF;	—

Countries

China

Contacts

Public ContactZheng Fangfang

Suqian People's Hospital of Nanjing Drum Tower Hospital Group

xin7998@163.com+86 15050513005

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026